🚀 VC round data is live in beta, check it out!
Isofol Medical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Isofol Medical and similar public comparables like Lexaria Bioscience, Xbrane Biopharma, NeuroSense Therapeutics, Vistagen Therapeutics and more.
Isofol Medical Overview
About Isofol Medical
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
Founded
2008
HQ
Employees
4
Website
Sectors
Financials (LTM)
EV
$12M
Isofol Medical Financials
Isofol Medical reported last 12-month revenue of — and negative EBITDA of ($7M).
In the same LTM period, Isofol Medical generated — in gross profit, ($7M) in EBITDA losses, and had net loss of ($6M).
Revenue (LTM)
Isofol Medical P&L
In the most recent fiscal year, Isofol Medical reported revenue of — and EBITDA of ($6M).
Isofol Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($7M) | XXX | ($6M) | XXX | XXX | XXX |
| Net Profit | ($6M) | XXX | ($6M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Isofol Medical Stock Performance
Isofol Medical has current market cap of $25M, and enterprise value of $12M.
Market Cap Evolution
Isofol Medical's stock price is $0.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12M | $25M | 1.1% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIsofol Medical Valuation Multiples
Isofol Medical trades at (1.8x) EV/EBITDA.
EV / Revenue (LTM)
Isofol Medical Financial Valuation Multiples
As of April 18, 2026, Isofol Medical has market cap of $25M and EV of $12M.
Equity research analysts estimate Isofol Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Isofol Medical has a P/E ratio of (4.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $25M | XXX | $25M | XXX | XXX | XXX |
| EV (current) | $12M | XXX | $12M | XXX | XXX | XXX |
| EV/EBITDA | (1.8x) | XXX | (2.0x) | XXX | XXX | XXX |
| EV/EBIT | (1.8x) | XXX | (1.9x) | XXX | XXX | XXX |
| P/E | (4.0x) | XXX | (4.3x) | XXX | XXX | XXX |
| EV/FCF | (1.9x) | XXX | (2.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Isofol Medical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Isofol Medical Margins & Growth Rates
Isofol Medical's revenue in the last fiscal year declined by (100%).
Isofol Medical's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.5M for the same period.
Isofol Medical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | (15%) | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Isofol Medical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Isofol Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Lexaria Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Xbrane Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| NeuroSense Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vistagen Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Xintela | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Isofol Medical M&A Activity
Isofol Medical acquired XXX companies to date.
Last acquisition by Isofol Medical was on XXXXXXXX, XXXXX. Isofol Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Isofol Medical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIsofol Medical Investment Activity
Isofol Medical invested in XXX companies to date.
Isofol Medical made its latest investment on XXXXXXXX, XXXXX. Isofol Medical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Isofol Medical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Isofol Medical
| When was Isofol Medical founded? | Isofol Medical was founded in 2008. |
| Where is Isofol Medical headquartered? | Isofol Medical is headquartered in Sweden. |
| How many employees does Isofol Medical have? | As of today, Isofol Medical has over 4 employees. |
| Who is the CEO of Isofol Medical? | Isofol Medical's CEO is Petter Segelman Lindqvist. |
| Is Isofol Medical publicly listed? | Yes, Isofol Medical is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Isofol Medical? | Isofol Medical trades under ISOFOL ticker. |
| When did Isofol Medical go public? | Isofol Medical went public in 2017. |
| Who are competitors of Isofol Medical? | Isofol Medical main competitors are Lexaria Bioscience, Xbrane Biopharma, NeuroSense Therapeutics, Vistagen Therapeutics. |
| What is the current market cap of Isofol Medical? | Isofol Medical's current market cap is $25M. |
| Is Isofol Medical profitable? | No, Isofol Medical is not profitable. |
| What is the current EBITDA of Isofol Medical? | Isofol Medical has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Isofol Medical? | Current EBITDA multiple of Isofol Medical is (1.8x). |
| What is the current FCF of Isofol Medical? | Isofol Medical's last 12 months FCF is ($6M). |
| What is the current EV/FCF multiple of Isofol Medical? | Current FCF multiple of Isofol Medical is (1.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.